
Cure
Overview
Surgical robotics is evolving beyond traditional operating-room systems, with emerging companies developing specialized platforms for minimally invasive procedures and AI-assisted surgery.
A hospital buying a surgical robot has to answer a question that the purchase price alone cannot settle. Will enough surgeons use it often enough to justify the cost? For robotics companies, that means making a case for how the system fits the hospital’s operating rooms, procedure volumes, and budget.
Intuitive Surgical reported more than 12,000 da Vinci surgical robots installed worldwide as of Sept. 30, 2026, up 12% from a year earlier. That gives challengers a sense of the scale they are up against. Some are designing systems for specific procedures or for settings such as ambulatory surgery centers.
Hospitals can buy systems outright, lease them, or pay on a per-case basis, said Shay O’Mara, MD, MBA, OhioHealth’s clinical vice president of surgery. A system can also bring recurring costs for disposable instruments and, in some cases, require changes to the operating room. O’Mara said hospitals weigh those costs against expected case volume, operating-room efficiency, and the potential for better patient outcomes. The clinical benefits compared with conventional laparoscopy vary by procedure, he said.
The companies below range from established commercial challengers and companies in early launch to teams still testing their systems. Their approaches show where robotics developers are looking for an opening and what they still have to prove.
Distalmotion
Sector: Multiport soft-tissue laparoscopy aimed at ambulatory surgery centers for hernia, gallbladder, gynecology
HQ: Lausanne (Epalinges), Switzerland; US office in Cleveland, Ohio
Founded: 2012
Key Leaders: Greg Roche, CEO; Tony Collins, CFO; Lionel Flaction, CTO
Employees: 201-500
Stage: Privately held; Series G
Financial Snapshot: $150M Series G in November 2025; total equity raised ~$390M
Notable Investors: Revival Healthcare Capital; Johnson & Johnson Innovation; Helvetica Capital; Numan Wealth Partners; Swiss Entrepreneurs Foundation; Kinled Holding
Key Products: Dexter, is a mobile, bedside robotic surgery system with a small footprint, an open-architecture endoscope arm, and single-use, fully wristed instruments. It is compatible with 5–10 mm endoscopes, including 4K fluorescence imaging systems.
Regulatory Status: FDA-cleared for inguinal hernia, sacrocolpopexy and endometriosis resection, cholecystectomy, benign hysterectomy, and inguinal hernia; IDE approved for a myomectomy trial; European CE marked.
Business Model: Positioned on per-procedure economics for ASCs; single-use instruments, no proprietary instrument ecosystem required
Systems Installed or Procedures: More than 4,000 patients treated globally per 2026 numbers.
Recent Highlights: In October 2026, the company announced that it entered into a senior secured term loan facility of up to $70 million with Perceptive Advisors. The funds will be used to support its US ambulatory surgery center market and for development of Dexter and its instrument portfolio. In August 2026, Distalmotion announced that it received FDA 510(k) clearance for ventral hernia repair with its Dexter Robotic Surgery System based on the Robotic minimAlly invasive Ventral hErNia repair (RAVEN) Study.
PROCEPT BioRobotics
Sector: Urology
HQ: San Jose, CA
Founded: 2007
Key Leaders: Larry Wood, CEO; Kevin Waters, CFO; Barry Templin, CTO
Employees: 501-1,000
Stage: Public, commercial
Financial Snapshot: In 2026, the company predicted its full-year financial results for fiscal year 2026 to be between $390M and $410M. The company reported $98.3M in Q3 2026 revenue, this is up 18% year over year.
Notable Investors: Publicly traded; institutional holders
Key Products: Aquabeam and Hydros are AI-enabled robotic systems for benign prostate hyperplasia (BPH); Aquablation provides heat-free waterjet tissue removal for BPH
Regulatory Status: FDA-cleared for BPH; prostate cancer uses investigational
Business Model: Capital sale and lease of systems plus per-procedure disposable handpieces
Systems Installed or Procedures: 912 systems globally; 718 in the U.S. as of December 31, 2025; ~12,200 U.S. procedures in Q1 2026
Recent Highlights: On August 4, 2026, the company announced total revenue of $94.5 million for the second quarter of 2026, an increase of 19% compared to the prior year period in 2025. On May 28, 2026, the company stated that it fully enrolled participants for its randomized WATER IV study evaluating Aquablation therapy versus radical prostatectomy. It also announced FDA Investigational Device Exemption (IDE) approval for a second randomized protocol evaluating Aquablation therapy versus active surveillance.
Noah Medical
Sector: Interventional pulmonology
HQ: San Carlos, CA
Founded: 2018
Key Leaders: Jian Zhang, PhD, founder & CEO; Ivy Li, CFO; Krish Bhadra, MD, Chief Pulmonary Advisor
Employees: 201-500
Stage: Privately held, Series B1
Financial Snapshot: ~$230M Series B1 round in Sept 2025
Notable Investors: Aramco Ventures, CB Insights, SoftBank Vision Fund, Prosperity7 Ventures, Tiger Global, Hillhouse, Sequoia China, Shangbay Capital, Uphonest Capital, Sunmed Capital, LYFE Capital, 1955 Capital, and AME Cloud Ventures.
Key Products: Galaxy System, designed to let physicians navigate, locate, and biopsy small, hard-to-reach lung nodules in the periphery of the lungs
Regulatory Status: The Galaxy System received FDA 510(k) clearance in March 2023. In April 2025, the FDA issued Noah Medical a warning letter citing deficiencies in its quality system and adverse-event reporting for the Galaxy System. The letter said Noah had begun reviewing past complaints and planned to revise its reporting process. In August 2026, a Noah spokesperson told MassDevice that the FDA was working to schedule a follow-up inspection.
Business Model: Capital system plus per-procedure single-use scopes
Systems Installed or Procedures: In September 2026, the company reported more than 16,000 procedures in the United States. There are also 60+ clinical sites using the Galaxy System, 250+ innovators and industry leaders.
Recent Highlights: In September 2026, Noah Medical announced that it completed its first commercial procedure in Asia using the Galaxy System at Prince of Wales Hospital in Hong Kong. On August 11, 2026, the company announced that it launched Galaxy II, the next evolution of its robotic-assisted bronchoscopy platform.
MMI (Medical Microinstruments)
Sector: Open soft-tissue microsurgery (lymphatic, reconstructive and nerve repair)
HQ: Jacksonville, FL
Founded: 2015
Key Leaders: Mark Toland, CEO; Caleb Moore, CFO; Tara Shea Micko, VP of Commercial Operations
Employees: 200+
Stage: Series D
Financial Snapshot: $125M Series D, following $110M Series C in February 2024, and $75M Series B in 2022
Notable Investors: Angelini Ventures, S3 Ventures, Wellington Partners, Andera Partners, Panakès Partners, Fountain Healthcare, Sambatech, Deerfield Management, RA Capital, BioStar Capital, Fidelity Management & Research Company
Key Products: Symani Surgical System with NanoWrist microinstruments for tremor reduction and motion scaling; Synaptix Digital Surgery Platform, a digital ecosystem designed to connect with the Symani system
Regulatory Status: The Symani system received FDA De Novo authorization on April 5, 2024. The NanoWrist Scissors and Forceps received 510(k) clearance in November 2025, The FDA's 510(k) summary describes them as instruments for soft-tissue dissection.
Business Model: Capital system plus single-use instruments and sutures; distribution partners are abroad (Gunze in Japan, ab medica in Italy). MMI has also announced distribution agreements with Gunze Medical in Japan and ab medica in Italy.
Systems Installed or Procedures: ~50 systems worldwide and ~3,500 procedures
Recent Highlights: In October 2026, the company raised $125M in Series D to accelerate commercial growth of its Symani Surgical System worldwide. In June 2026, MMI received FDA Approval to advance to Phase II of patient enrollment in its REMIND Microsurgical Study in Alzheimer’s patients. In April 2026, the company launched the first robotic microsurgical suture, following FDA clearance for its dissection instruments in December 2025.
CMR Surgical
Sector: Multiport soft-tissue laparoscopy for general, colorectal, gynecology, urology, thoracic procedures
HQ: Cambridge, UK; US sales run through Stryker
Founded: 2014
Key Leaders: Massimiliano Colella, CEO; Chris Fryer, CTO; Andre Nel, CFO
Employees: 201-500
Stage: Late-stage venture backed
Financial Snapshot: Secured more $200M in April 2025 financing round that includes a combination of equity and debt; Stryker agreed in October 2026 to a ~$400M preferred equity investment subject to closing conditions.
Notable Investors: Ally Bridge Group, Cambridge Innovation Capital, Chimera, Escala Capital, GE HealthCare, Lightrock, LGT, PFM Health Sciences, RPMI Railpen, SoftBank, Watrium, and Zuig
Key Products: Versius and second-generation Versius Plus are modular, bedside-cart arms with an open console; Versius Connect data ecosystem
Regulatory Status: Versius Plus FDA-cleared in December 2025; 510(k) for gynecology in October 2026; CE/UKCA marked for use in pediatrics in January 2026
Business Model: In the US, Stryker is exclusive sales agent
Systems Installed or Procedures: 45,000+ patients treated
Recent Highlights: In October 2026, the company announced a strategic equity investment of approximately $400 million by Stryker with an exclusive option for Stryker to acquire the remaining equity of CMR Surgical, and an exclusive U.S. commercial agency agreement for the Versius portfolio. In July 2026, CMR and NVIDIA showcased a research simulation using Versius Plus and NVIDIA's Isaac for Healthcare platform. CMR also reported that it had become the largest contributor to Open-H Embodiment, an open dataset for healthcare robotics.
Virtual Incision
Sector: Colectomy and gynecology
HQ: Lincoln, NE
Founded: 2006
Key Leaders: Jim Alecxih, President & CEO; Piet Hinoul MD, Chief Medical Officer; Rob Laird, Chief Operating Officer
Employees: 11-50
Stage: Series C
Financial Snapshot: $46M Series C was announced in November 2021. In September 2023, the company announced a further $30 million extension. That brings the publicly announced Series C financing to $76 million.
Notable Investors: Bluestem Capital, Endeavour Vision, Baird Capital, cultivate(MD) Capital Funds, PrairieGold Venture Partners, Arboretum Ventures, and InVivium Capital
Key Products: MIRA Surgical System, ~2 lb, drape- and dock-free
Regulatory Status:FDA granted De Novo authorization for MIRA in February 2024 for colon mobilization during minimally invasive colectomy in adults meeting specified height and weight criteria. On August 20, 2026, FDA granted 510(k) clearance expanding the indication to include minimally invasive benign (sub-)total hysterectomy, with or without salpingectomy, subject to patient eligibility criteria.
Business Model: Capital sale to hospitals and surgery centers and sold as a standalone or a complement to an existing mainframe robot.
Systems Installed or Procedures: Not disclosed
Recent Highlights: In August 2026, the company announced that it was granted 510(k) clearance from the FDA for the use of MIRA in benign hysterectomy procedures, moving MIRA beyond colectomy into gynecology.
Microbot Medical
Sector/Specialty: Peripheral endovascular and interventional radiology
HQ: Hingham, MA
Founded: 2010
Key Leaders: Harel Gadot, CEO, President & Chairman; Simon Sharon, CTO; Juan Diaz-Cartelle, MD, CMO; Rachel Vaknin, CFO
Employees: 11-50
Stage: Public
Financial Snapshot: Market cap ~$71.87M as of November 2026
Key Products: Liberty Endovascular Robotic System, single-use, remotely operated robot for peripheral endovascular procedures
Regulatory Status: FDA 510(k) cleared; cleared in Israel
Business Model: Fully disposable per-procedure robot; no capital purchase or dedicated infrastructure
Systems Installed or Procedures: Customers across multiple U.S. states; first California and West Coast customer announced October 2026
Recent Highlights/Why It’s Worth Watching: On July 7, 2026, the company reported greater than 100% growth in revenue and new customers for the second quarter which ended June 30, 2026. It also entered into an agreement with Lovell Government Services Inc., to serve federal healthcare systems, such as the Veterans Health Administration, a division of the U.S. Department of Veteran Affairs. On April 13, 2026, Microbot Medical announced its Full U.S. Market Release of the Liberty System.
Mendaera
Sector: Needle-based interventions for kidney access for PCNL first; vascular access, biopsies
HQ: San Mateo, CA
Founded: 2020
Key Leaders: Josh DeFonzo, Co-founder & CEO; Jason Wilson, Co-founder & CTO; Anant Ahuja, CFO
Employees: 51-200
Stage: Series B
Financial Snapshot:Mendaera reports more than $130 million raised to date.
Notable Investors: Threshold Ventures; Lux Capital; PFM Health Sciences; Founders Fund; Averin Capital; HighlandX; and Puma Venture Capital.
Key Products: Focalist is a handheld robotic guidance system that combines robotics, ultrasound imaging, and guidance software. The robotic component attaches to a compatible ultrasound probe, but the complete system also includes a cart and other components.
Regulatory Status: Focalist was FDA 510(k) cleared in July 2025
Business Model: Builds an open/compatible architecture that integrates with portable ultrasound platforms, such as EchoNous and Butterfly Network
Systems Installed or Procedures:First procedures performed at Mayo Clinic Arizona; broader adoption metrics not publicly disclosed.
Recent Highlights: In September 2026, Mendaera highlighted a urologist at the University of Alabama at Birmingham using Focalist for kidney access during PCNL, providing another institutional adoption milestone beyond its initial procedures at Mayo Clinic Arizona. In October 2026, the company rolled out Focalist paired with Butterfly’s iQ3 probe, which was a move from limited launch to broader commercial use.
Levita Magnetics
Sector: Laparoscopic general surgery (gallbladder, bariatric, urology assists) using magnetic organ retraction
HQ: Mountain View, CA
Founded: 2011
Key Leaders: Alberto Rodriguez-Navarro, MD, Founder, CEO & President
Employees: 11-50
Stage: Series D
Financial Snapshot:$30.7 million raised in the April 2026 Series D, according to Forge
Notable Investors: Aurus Capital, Ballast Capital, SPRIG Equity, Ataria Ventures, Carao Ventures, MedTex Ventures, Fen Ventures, Amarena and Vizcaya
Key Products: MARS (Magnetic-Assisted Robotic Surgery) platform; Levita Magnetic Surgical System with shaftless magnetic graspers. Magnetic technology is used to manipulate internal graspers and retract organs or tissue from outside the body. MARS adds robotic assistance, including surgeon-controlled positioning and enhanced visualization.
Regulatory Status: The Magnetic Surgical System received earlier FDA clearances, including 2018 and 2020. The Surgeon Controlled Arm received 510(k) clearance on August 4, 2023. The MSS received expanded clearance in June 2025 for bariatric and hiatal hernia procedures, followed by pediatric clearance in November 2025.
Business Model: MARS can work alongside other robots (used with da Vinci SP at UT Southwestern)
Systems Installed or Procedures: More than 1,000 procedures performed using MARS as of July 2025. The 1,000th procedure was a gastric bypass performed at Stanford University Hospital.
Recent Highlights: In November 2025, Levita’s MARS system Achieved FDA Clearance for pediatric use and Cleveland Clinic Children’s was the first clinic to perform surgery with it. In June 2025, the company expanded clearance for its MARS system.
EndoQuest Robotics
Sector: Robotic endoscopic submucosal dissection (ESD) of lesions in the rectum and sigmoid colon
HQ: Houston, TX
Founded: 2017
Key Leaders: Jared Eben, COO; Todd Wilson, MD, CMO
Employees: 51-200
Stage: Series D-2
Financial Snapshot: Raised $232M
Notable Investors: Crescent Enterprises; McNair
Key Products: Endoluminal Surgical (ELS) System, a flexible multi-instrument robot
Regulatory Status: Investigational. PARADIGM pivotal IDE trial fully enrolled in July 2026
Business Model: Plans to sell its robotic surgical platforms, patient carts, consoles, and specialized flexible instruments directly to hospitals, ambulatory surgical centers, and specialized medical clinics
Systems Installed or Procedures: In PARADIGM Trial, there were 50 robotic ESD procedures in 49 subjects by six investigators; preliminary data showed 100% en bloc resection with no conversions
Recent Highlights: In November 2025, the company announced the successful completion of two robotic transoral gastric reconstruction procedures using its Endoluminal Surgical (ELS) System.
Capstan Medical
Sector: Robot-delivered transcatheter mitral valve replacement (TMVR)
HQ: Santa Cruz, CA
Founded: 2020
Key Leaders: Maggie Nixon, CEO; Dan Wallace, Founder; Meg Carr, Head of Regulatory and Clinical
Employees: 51-200
Stage: Series C
Financial Snapshot: $110 million Series C in December 2024; $31.4 million Series B in August 2023. The Series C announcement brought total publicly reported funding to more than $150 million.
Notable Investors: Eclipse; Yu Galaxy; Intuitive Ventures; Gideon Strategic Partners; Puma Venture Capital
Key Products: The Capstan Compass System is a platform designed to treat mitral and tricuspid valve disease through a catheter while the heart is still beating.
Regulatory Status: The first-in-human TMVR study (NCT06600191) is recruiting, with primary completion estimated December 2026 and overall study completion estimated December 2031. A separate early feasibility study (NCT07917208) is also recruiting in the United States as of November 2026. The 2028 FDA submission target is a company development goal, not an established regulatory milestone.
Business Model: A robotic platform combined with proprietary catheter-delivery instruments and replacement valve implants. Implant-plus-robot model implies per-procedure implant revenue.
Systems Installed or Procedures: First robotic TMVR cases in Santiago, Chile in March 2025
Recent Highlights: In March 2025, the company announced the completion of pioneering the first-in-human robotic assisted transcatheter mitral valve replacements at Hospital Clínico Universidad Católica in Santiago Chile. In November 2026, Capstan's separate early feasibility TMVR study (NCT07917208) began recruiting at U.S. sites, including The Christ Hospital in Cincinnati. This represents progress toward expanding clinical evaluation beyond its initial international first-in-human experience.
XCath
Sector: Neurovascular endovascular (stroke thrombectomy, brain aneurysms)
HQ: Houston, TX
Founded: 2017
Key Leaders: Eduardo Fonseca, CEO; Nicholas Drysdale, CFO
Employees: 51-200
Stage: Series C
Financial snapshot: $30M raised in Series C for a total of $92M
Notable Investors: Crescent Enterprises; Fred Moll
Key Products: Iris endovascular robotic system, is an endovascular robotic platform designed to manipulate multiple neurovascular instruments, including guidewires and catheters. It supports both local robotic-assisted procedures and remote telerobotic procedures.
Regulatory Status: In September 2026, the company received FDA Breakthrough Device designation for Iris, its robotic system for remote mechanical thrombectomy in acute ischemic stroke.
Business Model: This is a robotic platform for hospitals and neurovascular centers, with a potential hub-and-spoke approach. Commercial pricing and revenue structure have not been disclosed.
Systems Installed or Procedures: No commercial installations reported; four patients treated in two investigational programs. In March 2026, XCath performed its first telerobotic stroke procedure on a human as part of its Operation Robo Angel clinical study. In November 2025, the company announced its first-in-human aneurysm treatment occurred in three patients in Panama City.
Recent Highlights: In September 2026, the company announced the FDA granted Breakthrough Device designation for its Iris surgical robotic system for remote robotic-assisted mechanical thrombectomy in patients with acute ischemic stroke. In March 2026, XCath completed its first telerobotic stroke procedure in a human as part of a clinical investigation called Operation Robo Angel. The neurosurgeon operated the Iris system from a control station in Santiago, Panama, to treat a patient more than 120 miles away at The Panama Clinic in Panama City.
Andromeda Surgical
Sector: Endourology. Robot-assisted HoLEP (laser enucleation of the prostate for BPH)
HQ: South San Francisco, CA
Founded: 2023
Key Leaders: Nick Damiano, Co-Founder & CEO; Kartik Tiwari, Co-Founder & CTO
Employees: 11-50
Stage: Series A
Financial Snapshot: The company recently raised $15 million Series A, bringing total reported funding to approximately $30 million.
Notable Investors: Standard Capital, VOX Capital, Cybernetix Ventures, NZVC, WestWave Capital, Zelda Ventures, Rebel Fund, Zeno Partners, Techable VC, Pioneer Fund, Y Combinator, Lingotto Innovation, Alumni Ventures, Phaze Ventures
Key Products:Beacon surgical robotics platform, initially developed for robotic-assisted HoLEP (RoLEP). It combines a tablet-based surgeon interface, anatomical navigation, and software designed to support progressively autonomous surgical tasks.
Regulatory Status: The product is available for sale in Canada and New Zealand but isn’t FDA-cleared yet in the U.S. The ASTRA clinical study is ongoing, with primary completion estimated for December 2026.
Business Model: This product is a software-enabled surgical robotics platform combining robotic hardware, anatomical navigation, and AI-guided surgical assistance. The company is pursuing hospital-based sales and deployments. Specific pricing, leasing arrangements, and recurring software revenue have not been disclosed.
Systems Installed or Procedures: In 2024, the first robotic-assisted HoLEP (RoLEP) procedure was performed at Universidad Católica in Santiago, Chile, using a tablet-based interface.
Recent Highlights: In 2026, the company stated that it had successful clinical trials underway in various countries, and that it’s planning to scale beyond HoLEP procedures into other surgical specialties. The company’s vision is to become “the Tesla of Surgical Robotics.” In August 2026, the company announced clearance to launch commercially in New Zealand. And in fall 2026 it received Health Canada's Medical Device Licence, making Canada its second announced market for commercial launch. The company also reported more than 40 patients treated across three countries.






